|
|||||
|
|
Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers |
|
| Authors: | Maria Hernandez-Valladares Marc Vaudel Frode Selheim Frode Berven Øystein Bruserud |
| Affiliation: | 1. Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway;2. Proteomics Unit, Department of Biomedicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway;3. KG Jebsen Center for Diabetes Research, Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway;4. Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway;5. Proteomics Unit, Department of Biomedicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway |
| Abstract: | Introduction: Mass spectrometry (MS)-based proteomics has become an indispensable tool for the characterization of the proteome and its post-translational modifications (PTM). In addition to standard protein sequence databases, proteogenomics strategies search the spectral data against the theoretical spectra obtained from customized protein sequence databases. Up to date, there are no published proteogenomics studies on acute myeloid leukemia (AML) samples. Areas covered: Proteogenomics involves the understanding of genomic and proteomic data. The intersection of both datatypes requires advanced bioinformatics skills. A standard proteogenomics workflow that could be used for the study of AML samples is described. The generation of customized protein sequence databases as well as bioinformatics tools and pipelines commonly used in proteogenomics are discussed in detail. Expert commentary: Drawing on evidence from recent cancer proteogenomics studies and taking into account the public availability of AML genomic data, the interpretation of present and future MS-based AML proteomic data using AML-specific protein sequence databases could discover new biological mechanisms and targets in AML. However, proteogenomics workflows including bioinformatics guidelines can be challenging for the wide AML research community. It is expected that further automation and simplification of the bioinformatics procedures might attract AML investigators to adopt the proteogenomics strategy. |
| Keywords: | Acute myeloid leukemia bioinformatics cancer databases genomics mutations proteogenomics proteomics variants |